Close Menu

NEW YORK – Germline genetic testing after tumor sequencing can uncover clinically actionable alterations among cancer patients, according to a new study from genetic testing company Invitae and its collaborators. 

Germline genetic testing is typically recommended for cancer patients who are thought to have hereditary disease, while tumor sequencing is generally performed on patients with advanced disease, but both can inform cancer treatment approaches.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Dec
02
Sponsored by
Qiagen

The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.